Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zenith DrugsNSE:ZENITHDRUG +7.48%40 EV-to-EBITDA is 8.13 as of Sep. 09, 2026, which is 11% below its 10-year median of 9.10. GuruFocus rates NSE:ZENITHDRUG with a GF Score™ of 40/100. The stock has 5 warning signs investors should review. Among 726 Drug Manufacturers companies, Zenith Drugs ranks better than 70.8% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Zenith Drugs's enterprise value is ₹1,386 Mil.
Zenith Drugs's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹170 Mil. Therefore, Zenith Drugs's EV-to-EBITDA for today is 8.13.
The historical rank and industry rank for Zenith Drugs's EV-to-EBITDA or its related term are showing as below:
NSE:ZENITHDRUG'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.56 Med: 9.1 Max: 19.72
Current: 8.13
During the past 6 years, the highest EV-to-EBITDA of Zenith Drugs was 19.72. The lowest was 6.56. And the median was 9.10.
NSE:ZENITHDRUG's EV-to-EBITDA is ranked better than 70.8% of 726
companies
in the Drug Manufacturers industry
Industry Median: 13.4
vs NSE:ZENITHDRUG: 8.13
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zenith Drugs's PE Ratio (TTM) for today is calculated as:
Zenith Drugs's share price for today is ₹48.10.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Zenith Drugs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹2.300.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Zenith Drugs's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Zenith Drugs's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zenith Drugs EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zenith Drugs's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Zenith Drugs's EV-to-EBITDA falls into.
Zenith Drugs's current Enterprise Value is ₹1,386 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Zenith Drugs's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹170 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zenith Drugs (NSE:ZENITHDRUG) has a EV-to-EBITDA of 8.13 as of Sep. 09, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Zenith Drugs. This is 11% below median its historical median of 9.10. Over the past decade, Zenith Drugs' EV-to-EBITDA has ranged from 6.56 to 19.72. According to the industry distribution chart, Zenith Drugs ranks #212 out of 726 companies in the Drug Manufacturers industry, placing it in the top 29.2%.
Is Zenith Drugs' EV-to-EBITDA too high?
Zenith Drugs' current EV-to-EBITDA of 8.13 is 11% below median its 10-year median of 9.10. Over the past 10 years, this metric has ranged from a low of 6.56 to a high of 19.72. The Drug Manufacturers industry median EV-to-EBITDA is 13.40. Zenith Drugs' value of 8.13 is 39.3% below this industry median. Based on the distribution chart, Zenith Drugs ranks #212 out of 726 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Zenith Drugs has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Zenith Drugs' EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zenith Drugs ranks #212 out of 726 companies for EV-to-EBITDA. This puts Zenith Drugs in the upper half of its industry. The industry median EV-to-EBITDA is 13.40. Zenith Drugs' value of 8.13 is 39.3% below this benchmark. Historically, Zenith Drugs' own EV-to-EBITDA has ranged from 6.56 to 19.72 over the past decade. While the company's 10-year median is 9.10 vs. the industry median of 13.40, Zenith Drugs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.40, based on 726 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zenith Drugs's current EV-to-EBITDA of 8.13 is 39.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Zenith Drugs. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zenith Drugs's current EV-to-EBITDA is 8.13, which is 11% below median its own 10-year median of 9.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenith Drugs stock overvalued right now?
Zenith Drugs (NSE:ZENITHDRUG) has a current EV-to-EBITDA of 8.13. The current EV-to-EBITDA is 8.13, which is 11% below median its 10-year median of 9.10 and 39.3% below the Drug Manufacturers industry median of 13.40. Zenith Drugs' overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Zenith Drugs (NSE:ZENITHDRUG), the current EV-to-EBITDA is 8.13 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zenith Drugs Ltd is a pharmaceutical manufacturing and trading company. It offers a wide range of formulations in various forms such as ORS Powder, Liquid Orals, Ointments, Liquid Externals, Creams, Gels, Capsules, and Tablets. It is also into Generic Medicines.
40GF Score
Get the complete analysis for NSE:ZENITHDRUG
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ZENITHDRUG has been successfully added to your 
